Updated:
Tasly Pharmaceutical Co.
Tasly Pharmaceutical's Yan family office invests Chinese medicine wealth into pharma, biotech, and real estate across China and the US.
Tasly Pharmaceutical Co.
Yanxi Yan launched Tasly Pharmaceutical in Tianjin in 1994, initially focusing on cardiovascular and cancer treatments derived from traditional Chinese medicine. The company went public on the Shanghai Stock Exchange in 2002. Yan's son Yifeng Yan serves as Vice Chairman, indicating a succession plan embedded in the family office structure. The wealth originates from Tasly's position as one of China's largest producers of traditional Chinese medicine, with particular strength in Danshen-based products. Tasly's investment activities span pharmaceutical manufacturing, biotech research, and real estate development across China and international markets. The family office pursues direct investments in healthcare companies, particularly those focused on integrative medicine combining Chinese and Western approaches. Confirmed portfolio expansions include a San Jose, California research center for drug discovery and FDA trials. Deployment also targets infrastructure projects in Tianjin and other Chinese Tier-2 cities. The family office operates through Tasly's corporate structure rather than as a separate entity, though investment decisions appear centralized under the Yan family. The office employs a team of financial professionals, though exact headcount remains undisclosed. Philanthropic activities include the Tasly Medical Foundation, established in 2010, which supports cardiovascular disease research and rural healthcare access. The foundation is legally separated from the family office. In 2023, Tasly secured Chinese regulatory approval for a new stroke treatment, reinforcing strong operational linkage between the pharmaceutical company and family wealth. Tasly's key structural differentiator is its integration of traditional Chinese medicine with Western drug discovery and clinical trials. The family office benefits from proprietary insights into China's healthcare regulatory environment and distribution networks, giving it an edge in sourcing direct investments in Chinese biotech and pharmaceutical assets.
General information
Firm type
Single Family Office
Year founded
1994
AUM
Undisclosed
Location
Region
Asia
Country
China
City
Tianjin
Corporate office
Tianjin, China
Additional offices
Beijing · Seoul · San Jose
Principals
Yanxi Yan
Founder and Chairman
Yifeng Yan
Vice Chairman
Sector focus
Frequently asked questions
Who runs investment decisions at Tasly's family office?
Yanxi Yan, founder and chairman of Tasly Pharmaceutical, retains control over investment strategy. His son Yifeng Yan, Vice Chairman of the company, is expected to oversee the family office's deployment in coming years. Specific investment team composition is not publicly disclosed.
How does Tasly's family office source proprietary deal flow?
The office leverages Tasly Pharmaceutical's industry relationships in Chinese healthcare, regulatory knowledge, and distribution networks. Its R&D center in San Jose provides access to US biotech opportunities. The family also draws on real estate development expertise in Tianjin and other Chinese cities.
Is Tasly's family office structured as a single family office or does it operate more like a venture firm?
It operates as a single family office, closely integrated with Tasly Pharmaceutical's corporate structure. Investment decisions are made by the Yan family, with no external limited partners. The office does not run a venture fund separate from the company, though it makes direct investments in assets aligned with the family's core healthcare and real estate sectors.
Does Tasly's family office participate in fund commitments or only direct deals?
The family office appears to focus primarily on direct investments in pharmaceutical research, biotech startups, and real estate projects. There is no public record of fund commitments to external managers. The office's direct approach aligns with its operational roots in the pharmaceutical industry.
What investment stages does Tasly's family office typically target?
The office invests across stages, from early-stage biotech research to established real estate projects. Its R&D center in San Jose targets early-stage drug discovery, while real estate investments focus on development-stage projects in Chinese cities. The family has also made growth-stage investments in Chinese healthcare companies.
How is Tasly's family office related to Tasly Pharmaceutical?
The family office is the personal investment vehicle of the Yan family, which controls Tasly Pharmaceutical through their majority stake in the publicly traded company. The office operates within the same corporate ecosystem, sharing management and industry insights, but manages the family's personal wealth separately from the pharmaceutical business.
Where does Tasly's underlying wealth come from?
The wealth originates from Tasly Pharmaceutical, which Yanxi Yan founded in 1994 in Tianjin. The company became a leading producer of traditional Chinese medicine, particularly cardiovascular treatments. Tasly went public on the Shanghai Stock Exchange in 2002, and the Yan family's stake has generated substantial dividends and capital appreciation, valued at over $8 billion in market cap.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: